- Home
- LMAT
as 07-26-2024 4:00pm EST
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as LeMaitre Vascular Inc. LMAT prepares to release earnings report on 01 Aug 2024.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | BURLINGTON |
| Market Cap: | 1.9B | IPO Year: | 2006 |
| Target Price: | $77.57 | AVG Volume (30 days): | 146.0K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.50 | EPS Growth: | 61.29 |
| 52 Week Low/High: | $44.27 - $91.76 | Next Earning Date: | 08-01-2024 |
| Revenue: | $199,887,000 | Revenue Growth: | 18.16% |
| Revenue Growth (this year): | 13.37% | Revenue Growth (next year): | 7.96% |
Stock Insider Trading Activity of LeMaitre Vascular Inc. (LMAT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LeMaitre George W | LMAT | Chairman and CEO | Jul 16 '24 | Sell | $86.69 | 57,372 | $4,973,790.96 | 1,900,956 | SEC Form 4 |
| LeMaitre George W | LMAT | Chairman and CEO | Jul 12 '24 | Sell | $86.27 | 27,030 | $2,331,907.83 | 1,958,328 | SEC Form 4 |
| LeMaitre George W | LMAT | Chairman and CEO | Jul 12 '24 | Sell | $86.07 | 12,976 | $1,116,844.32 | 1,985,358 | SEC Form 4 |
| Ross Bridget A | LMAT | Director | May 16 '24 | Sell | $77.99 | 5,500 | $428,945.00 | 2,278 | SEC Form 4 |
| LeMaitre George W | LMAT | Chairman and CEO | May 13 '24 | Sell | $76.42 | 35,826 | $2,737,686.78 | 2,043,302 | SEC Form 4 |
| LeMaitre George W | LMAT | Chairman and CEO | May 13 '24 | Sell | $76.80 | 40,968 | $3,146,371.08 | 1,998,334 | SEC Form 4 |
| LeMaitre George W | LMAT | Chairman and CEO | May 6 '24 | Sell | $76.12 | 23,206 | $1,766,466.25 | 2,179,128 | SEC Form 4 |
| LeMaitre George W | LMAT | Chairman and CEO | May 6 '24 | Sell | $75.23 | 29,500 | $2,219,308.60 | 2,149,628 | SEC Form 4 |
| LeMaitre George W | LMAT | Chairman and CEO | May 6 '24 | Sell | $75.94 | 16,200 | $1,230,237.72 | 2,133,428 | SEC Form 4 |
| LeMaitre George W | LMAT | Chairman and CEO | May 6 '24 | Sell | $75.24 | 26,044 | $1,959,521.91 | 2,107,384 | SEC Form 4 |
| LeMaitre George W | LMAT | Chairman and CEO | May 6 '24 | Sell | $75.86 | 20,256 | $1,536,539.14 | 2,087,128 | SEC Form 4 |
| LeMaitre George W | LMAT | Chairman and CEO | May 6 '24 | Sell | $75.30 | 8,000 | $602,427.20 | 2,079,128 | SEC Form 4 |
| Roberts David B | LMAT | President and Director | May 6 '24 | Sell | $75.62 | 5,025 | $379,990.50 | 14,114 | SEC Form 4 |
| Kamke Trent G | LMAT | Senior V. P., Operations | Mar 8 '24 | Sell | $68.02 | 3,442 | $234,138.61 | 5,661 | SEC Form 4 |
| Kamke Trent G | LMAT | Senior V. P., Operations | Mar 8 '24 | Sell | $68.68 | 1,100 | $75,545.80 | 4,561 | SEC Form 4 |
| Roush John A | LMAT | Director | Mar 7 '24 | Sell | $69.00 | 7,500 | $517,500.00 | 2,278 | SEC Form 4 |
| Jasinski Lawrence J | LMAT | Director | Mar 5 '24 | Sell | $67.50 | 5,110 | $344,925.00 | 5,309 | SEC Form 4 |
| Pellegrino Joseph P JR | LMAT | Chief Financial Officer | Feb 29 '24 | Sell | $68.56 | 1,979 | $135,680.24 | 41,440 | SEC Form 4 |
| Pellegrino Joseph P JR | LMAT | Chief Financial Officer | Feb 29 '24 | Sell | $69.72 | 28,461 | $1,984,414.76 | 12,979 | SEC Form 4 |
| Pellegrino Joseph P JR | LMAT | Chief Financial Officer | Feb 29 '24 | Sell | $70.27 | 6,250 | $439,187.50 | 6,729 | SEC Form 4 |
| Pellegrino Joseph P JR | LMAT | Chief Financial Officer | Feb 29 '24 | Sell | $71.19 | 277 | $19,719.63 | 6,452 | SEC Form 4 |
| LeMaitre George W | LMAT | Chairman and CEO | Feb 29 '24 | Sell | $68.37 | 1,300 | $88,881.00 | 2,282,296 | SEC Form 4 |
| LeMaitre George W | LMAT | Chairman and CEO | Feb 29 '24 | Sell | $69.69 | 20,575 | $1,433,871.75 | 2,261,721 | SEC Form 4 |
| LeMaitre George W | LMAT | Chairman and CEO | Feb 29 '24 | Sell | $70.14 | 5,984 | $419,717.76 | 2,255,737 | SEC Form 4 |
| LeMaitre George W | LMAT | Chairman and CEO | Feb 29 '24 | Sell | $67.51 | 15,869 | $1,071,316.19 | 2,245,276 | SEC Form 4 |
Latest LeMaitre Vascular Inc. News
LMAT Breaking Stock News: Dive into LMAT Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
LMAT: Raising target price to $95.00
MT Newswires
8 days ago
LeMaitre Vascular Insider Sold Shares Worth $4,973,791, According to a Recent SEC Filing
Zacks
9 days ago
HLN vs. LMAT: Which Stock Is the Better Value Option?
Argus Research
10 days ago
LMAT: Raising target price to $91.00
GlobeNewswire
10 days ago
LeMaitre Will Announce Second Quarter 2024 Earnings Results August 1, 2024
Simply Wall St.
15 days ago
A Look At The Intrinsic Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Argus Research
17 days ago
LMAT: Raising target price to $88.00
Argus Research
24 days ago
LMAT: Lowering target price to $85.00
Compare LMAT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LMAT LeMaitre Vascular Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.